In summary, these data demonstrate delivery of OV to tumour via IHA administration, associated with viral replication and significant peripheral immune activation. Collectively, the data supports the need for future studies using IHA administration of OVs.

11 months ago

P1 data • Journal

CALR (Calreticulin)

5-fluorouracil • TG6002

over2years

Oncolytic virotherapy with intratumoral injection of vaccinia virus TG6002 and 5-fluorocytosine administration in dogs with malignant tumors. (PubMed, Mol Ther Oncolytics)

Viral replication, 5-fluorouracil synthesis, and tumor microenvironment changes were more frequently observed with higher TG6002 doses. This study confirmed the replicative properties, targeted chemotherapy synthesis, and reversion of the immunosuppressive tumor microenvironment in dogs with spontaneous malignant tumors treated with TG6002 and 5-fluorocytosine.

over 2 years ago

Journal • Oncolytic virus

5-fluorouracil • TG6002

over2years

Study of TG6002 (VV TK-RR-FCU1) in Combination With 5-FC in Patients With Advanced Gastro-intestinal Tumors. (clinicaltrials.gov)

P1/2, N=51, Terminated, Transgene | N=101 --> 51 | Trial completion date: Sep 2023 --> Feb 2023 | Recruiting --> Terminated | Trial primary completion date: Sep 2022 --> Feb 2023; Study has been terminated after Phase I part on 23 February 2023

over 2 years ago

Enrollment change • Trial completion date • Trial termination • Trial primary completion date • Combination therapy • Metastases

TG6002

over2years

Study of Intrahepatic Arterial Infusion of TG6002 in Combination With 5-FC in Patients With Metastatic Colorectal Cancer (clinicaltrials.gov)

P2a, N=15, Terminated, Transgene | N=75 --> 15 | Trial completion date: Sep 2023 --> Feb 2023 | Recruiting --> Terminated; Study has been terminated after Phase I part on 23 February 2023

over 2 years ago

Enrollment change • Trial completion date • Trial termination • Combination therapy • Metastases

TG6002